Pancreatic Cancer Research

ResearcherUniversité de PoitiersActive in the last 2 years

David Tougeron

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8065-9635; OpenAlex author ID A5040688022. Sources: OpenAlex.

Their work

Papers
25 (first author 3, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
78
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: 1 paper · 2022: 3 papers · 2023: 4 papers · 2024: 2 papers · 2025: 5 papers · 2026: 2 papers

Papers 25

  1. Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic… Co-author DOI 10.1016/j.eclinm.2026.103998↗
  2. Analysis of diagnostic pathway and therapeutic delay for patients with pancreatic adenocarcinoma: a French retrospective study. Last author DOI 10.1177/17562848261428776↗
  3. Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study). Last author DOI 10.1016/j.esmogo.2025.100142↗
  4. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Last author DOI 10.1093/oncolo/oyaf125↗
  5. Real-world efficacy of nanoliposomal irinotecan in patients with advanced pancreatic cancer. Co-author DOI 10.1186/s12885-025-15346-8↗
  6. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  7. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  8. Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study. Last author DOI 10.1007/s00330-024-10613-x↗
  9. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective… First author DOI 10.1016/j.ejca.2024.115051↗
  10. Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study. Last author DOI 10.1016/j.dld.2023.03.011↗
  11. Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre observational cohort study (CAPANCOGEN). Co-author DOI 10.1016/j.pan.2023.06.010↗
  12. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  13. KRAS G12C inhibitors: also a new promising new targeted therapy in advanced pancreatic adenocarcinoma? First author DOI 10.21037/tcr-23-1629↗
  14. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective obs… Co-author DOI 10.1016/j.ejca.2022.01.040↗
  15. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Co-author DOI 10.1038/s41416-022-01713-w↗
  16. Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world A… Co-author DOI 10.1038/s41416-022-01734-5↗
  17. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Co-author DOI 10.1038/s41416-021-01341-w↗
  18. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter … First author DOI 10.1016/j.clinre.2019.08.009↗
  19. Erratum to "Irreversible electroporation for locally advanced pancreatic cancer" [Diagn. Interv. Imaging 97 (2016) 1297-1304]. Last author DOI 10.1016/j.diii.2019.12.011↗
  20. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized … Co-author DOI 10.1016/j.ejca.2019.10.020↗
  21. Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label,… Co-author DOI 10.1016/j.ejca.2020.02.004↗
  22. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Co-author DOI 10.1177/1756284819878660↗
  23. Irreversible Electroporation for Locally Advanced Pancreatic Cancer: Where Do We Stand in 2017? Last author DOI 10.1097/mpa.0000000000000793↗
  24. Irreversible electroporation for locally advanced pancreatic cancer. Last author DOI 10.1016/j.diii.2016.10.001↗
  25. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Co-author DOI 10.1038/bjc.2015.328↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Camille Evrard · 6 shared papers, 2022–2026 · strength 1.20
  2. Julien Taı̈eb · 9 shared papers, 2015–2026 · strength 1.11
  3. Olivier Bouché · 7 shared papers, 2020–2025 · strength 1.00
  4. Nicolas Williet · 7 shared papers, 2019–2025 · strength 0.94
  5. Jean‐Baptiste Bachet · 7 shared papers, 2015–2026 · strength 0.86
  6. Simon Pernot · 7 shared papers, 2015–2026 · strength 0.85
  7. Marie Müller · 3 shared papers, 2023–2025 · strength 0.79
  8. Isabelle Trouilloud · 5 shared papers, 2019–2025 · strength 0.65
  9. Dominique Béchade · 5 shared papers, 2019–2025 · strength 0.59
  10. Pascal R. Hammel · 5 shared papers, 2015–2025 · strength 0.53
  11. Mathias Brügel · 3 shared papers, 2022–2025 · strength 0.51
  12. Anthony Turpin · 3 shared papers, 2022–2024 · strength 0.43
  13. Anna Pellat · 2 shared papers, 2024–2026 · strength 0.38
  14. Jean‐Frédéric Blanc · 2 shared papers, 2024–2025 · strength 0.38
  15. Édouard Auclin · 3 shared papers, 2021–2022 · strength 0.36
  16. Matthieu Sarabi · 3 shared papers, 2021–2022 · strength 0.36
  17. Gaël S. Roth · 2 shared papers, 2022–2025 · strength 0.35
  18. Christophe Tournigand · 3 shared papers, 2020–2025 · strength 0.33
  19. Fabienne Portales · 3 shared papers, 2020–2025 · strength 0.33
  20. Anne‐Laure Pointet · 3 shared papers, 2019–2025 · strength 0.33
  21. Frédéric Di Fiore · 2 shared papers, 2022–2026 · strength 0.33
  22. Christelle de la Fouchardière · 4 shared papers, 2015–2021 · strength 0.31
  23. Lysiane Marthey · 3 shared papers, 2015–2025 · strength 0.30
  24. Romain Coriat · 3 shared papers, 2015–2025 · strength 0.30
  25. Jean‐Pierre Tasu · 2 shared papers, 2017–2024 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.